Could Genomic Testing Be as Accessible as a Smartphone? Ana Cornell, CEO & Founder of Acorn Genetics

0:00-38:49

In this episode of Diagnosing Dx, David Filby is joined by Ana Cornell, Founder and CEO of Acorn Genetics. Ana started Acorn after experiencing first-hand how expensive and inaccessible genomic testing could be. While studying biomedical engineering at Northwestern, she began developing lower-cost genomic analysis technology before being selected for the highly competitive Thiel Fellowship, which gave her the opportunity to leave university and build Acorn full-time. The company’s long-term goal is to decentralise genomic analysis, bringing testing out of central laboratories and making it dramatically more accessible. But the route to that goal hasn’t been conventional. When regulatory changes disrupted Acorn’s original clinical launch plans, the company pivoted its technology into brewing, agriculture and water testing, finding early product-market fit, generating revenue and continuing to develop its sequencing platform. Ana shares why revenue has become central to Acorn’s strategy, how the company is approaching profitability, and why she still sees decentralised genomic analysis as the ultimate destination.

Publisher

Diagnosing Dx

Published

October 21, 2026

Duration

39 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Elevra Consulting

DD

Diagnosing Dx

@diagnosingdx

#genomictesting #anacornell #acorngenetics #lifesciences

The Nile